CIRM Awards $16.6M Grant to Stem Cell Research Company Working on Type 1 Diabetes Cure
The California Institute for Regenerative Medicine has granted diabetes therapy company ViaCyte a $16.6 million grant to develop a stem cell replacement therapy to treat patients with Type 1 diabetes. The therapy, which uses human embryonic stem cells to create pancreatic "islet" cells, could effectively cure patients with Type 1 diabetes.
- "ViaCyte Gets $16.6M Grant From CIRM To Develop VC-01 Diabetes Therapy Candidate" (Pharmaceutical Business Review, 9/11).
- "Potential Diabetes Cure Up for More Funding" (Fikes, U-T San Diego, 9/8).